Tag: FDA BIMO

US Oncology INDs: Safety Stopping Rules & DMC/DSMB Interfaces

Posted on digi By digi

US Oncology INDs: Safety Stopping Rules & DMC/DSMB Interfaces Designing Safety Stopping Rules and DMC/DSMB Interfaces for US Oncology INDs: A Practical, Inspection-Ready Playbook Why oncology trials live or die on their safety governance—and how to make it decisionable from Day 0 Begin with the decisions your trial must survive Oncology development stresses clinical safety…

Read More “US Oncology INDs: Safety Stopping Rules & DMC/DSMB Interfaces” »

US Regulatory Submissions

ADaM Derivations You Can Defend: Versioning, Unit Tests, Rationale

Posted on digi By digi

ADaM Derivations You Can Defend: Versioning, Unit Tests, Rationale ADaM Derivations You Can Defend: Versioning Discipline, Unit Tests That Catch Drift, and Rationale You Can Read in Court Outcome-first ADaM: derivations that survive questions, re-cuts, and inspection sprints What “defensible” means in practice Defensible ADaM derivations are those that a new reviewer can trace, reproduce,…

Read More “ADaM Derivations You Can Defend: Versioning, Unit Tests, Rationale” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

CMC Stability & Specifications for IND: Phase-Appropriate Justification

Posted on digi By digi

CMC Stability & Specifications for IND: Phase-Appropriate Justification Phase-Appropriate CMC Stability and Specifications for IND: How to Justify What’s “Enough” Without Overbuilding Why phase-appropriate stability and specifications decide IND speed—and how to justify them Start with the decision you need FDA to make The immediate outcome for a US-first early development program is straightforward: acceptance…

Read More “CMC Stability & Specifications for IND: Phase-Appropriate Justification” »

US Regulatory Submissions

Figure Standards That Stick: Labels, Ordering, Color Rules

Posted on digi By digi

Figure Standards That Stick: Labels, Ordering, Color Rules Figure Standards That Stick: Making Labels, Ordering, and Color Rules Reproducible and Reviewer-Friendly Why “figure standards” are a regulatory deliverable—not just a style preference Figures drive first impressions and hard questions For many reviewers, your figures are the first contact with the analysis, so they must answer…

Read More “Figure Standards That Stick: Labels, Ordering, Color Rules” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

Drug-Device Combination INDs: US Submission Nuances & Traps

Posted on digi By digi

Drug-Device Combination INDs: US Submission Nuances & Traps Drug–Device Combination INDs in the US: Practical Nuances, Hidden Traps, and an Inspection-Ready Playbook Why combination INDs are different—and how to avoid the traps that stall review Begin with PMOA and jurisdiction: the decision that shapes everything else Combination development succeeds or slips based on a single…

Read More “Drug-Device Combination INDs: US Submission Nuances & Traps” »

US Regulatory Submissions

Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy

Posted on digi By digi

Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy Bridging Foreign Data into a US IND: An Inspection-Ready Strategy for Acceptability, Traceability, and Real-World Timelines Why bridging foreign data is a speed lever—and how to make it acceptable the first time Start with the regulatory outcome, then design the bridge For many sponsors, the…

Read More “Bridging Foreign Data in US INDs: Acceptability & Evidence Strategy” »

US Regulatory Submissions

TLF Shells That Align Teams: Templates, Titles, Footnotes

Posted on digi By digi

TLF Shells That Align Teams: Templates, Titles, Footnotes TLF Shells That Align Teams: How to Design Templates, Titles, and Footnotes Everyone Can Defend Outcome-first TLF shells: align science, statistics, and inspection in one artifact What the shell must prove on Day 1 Well-made TLF shells do three jobs simultaneously: they communicate analysis intent to programmers…

Read More “TLF Shells That Align Teams: Templates, Titles, Footnotes” »

Biostats, CDISC & Traceability, Clinical Trial Operations & Data Integrity

IND on a Budget—What Not to Cut (Small Sponsor Tactics)

Posted on digi By digi

IND on a Budget—What Not to Cut (Small Sponsor Tactics) IND on a Budget—Smart Cuts, Not Blind Cuts: Small-Sponsor Tactics that Preserve Speed and Reviewability Outcome-Oriented Budgeting: Buy Time, De-Risk Holds, and Keep Your First-Patient-In Date Define the decision gates before you cut a dollar Lean programs win by funding decisions, not documents. Before trimming,…

Read More “IND on a Budget—What Not to Cut (Small Sponsor Tactics)” »

US Regulatory Submissions

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships

Posted on digi By digi

Rare-Disease Enrollment Playbook: Windows, Support, Partnerships Rare-Disease Enrollment Playbook: Managing Windows, Building Support, and Structuring Partnerships That Actually Deliver Why rare-disease enrollment is different—and the operating model that makes it predictable What breaks in “business-as-usual” enrollment for rare conditions In rare diseases, enrollment fails for structural reasons: low prevalence spread across wide geographies, heterogeneous diagnostic…

Read More “Rare-Disease Enrollment Playbook: Windows, Support, Partnerships” »

Clinical Trial Operations & Data Integrity, Study Operations & Enrollment

US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice

Posted on digi By digi

US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice Early Advice Pathways Compared: Getting Actionable FDA Meeting Outcomes vs EMA Scientific Advice (with UK/Global Notes) Why early advice determines your development velocity—and how to aim for decisionable outcomes Begin with a decision map, not a calendar Whether you pursue US or EU first,…

Read More “US vs EU Early Advice: FDA Meetings vs EMA Scientific Advice” »

US Regulatory Submissions